These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29016692)

  • 1. Benefit of early discharge among patients with low-risk pulmonary embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    PLoS One; 2017; 12(10):e0185022. PubMed ID: 29016692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of sPESI for risk stratification in patients with pulmonary embolism.
    Wells P; Peacock WF; Fermann GJ; Coleman CI; Wang L; Baser O; Schein J; Crivera C
    J Thromb Thrombolysis; 2019 Jul; 48(1):149-157. PubMed ID: 30729377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
    Peacock WF; Coleman CI; Wells P; Fermann GJ; Wang L; Baser O; Schein J; Crivera C
    J Health Econ Outcomes Res; 2019; 6(3):160-173. PubMed ID: 32685588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Crivera C; Bookhart B; Schein J
    Clin Ther; 2016 Nov; 38(11):2496-2503. PubMed ID: 27751675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
    Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism.
    Roy PM; Corsi DJ; Carrier M; Theogene A; de Wit C; Dennie C; Le Gal G; Delluc A; Moumneh T; Rodger M; Wells P; Gandara E
    J Thromb Haemost; 2017 Apr; 15(4):685-694. PubMed ID: 28106343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
    Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
    Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    J Health Econ Outcomes Res; 2019; 6(2):84-94. PubMed ID: 32685582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National trends in hospitalizations for venous thromboembolism.
    Brahmandam A; Abougergi MS; Ochoa Chaar CI
    J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):621-629.e2. PubMed ID: 28818212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.